Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 0 · 0%

Imiquimod vs cidofovir

Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia

Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).

1 finding from 1 review

Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.65, 2.74]
1 study · 176 participants
Moderate

Imiquimod vs cidofovir

Treatment discontinuation · women with high‐grade VIN

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for high‐grade vulval intraepithelial neoplasia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

TMP/SMX vs placebo, no treatment or non‐PCP drug

Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).

1 finding from 1 review

Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients 2014 · Cochrane Headline outcomes only
RR 0.28 [0.05, 1.7]
5 studies · 530 participants
Moderate